Audit: QRS - Nicotine for Health & Longevity

Audit conducted on 19/09/2026 06:33 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 369, 371, 377; time cells to ER lines 420 and 379; benefit/risk entries to the ER headings; monitoring rows to the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target for deliberate non-smoker use” (marker_7_target) and “remain unconfirmed” (at_a_glance) mirror the ER hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and breastfeeding remain in the Contraindications gate at full strength; the adenosine/dipyridamole absolute contraindication is not downgraded to an interaction.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER “Populations who should avoid Nicotine” list plus the ER’s own “Absolute contraindication”; no Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, net-reading tone of the ER Conclusion is carried into the at-a-glance and the tiered lists.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets, cadence and tiers give an actionable frame without exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and Monitoring cells state what the evidence describes rather than instructing a reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instructions; the footer disclaimer is the template’s own.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of recommend/advise/should-you constructions.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms (Child-Pugh Class C, HOMA-IR, transient ischaemic attack) are load-bearing decision-gate or biomarker terms taken verbatim from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items and tier lists are stripped to key facts; no mechanistic rationale carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no “you”/”your” in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Non-smoker performance protocol is presented first, with the full risk gate alongside.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Seven-marker monitoring panel, cotinine testing and six-monthly oral examination assume a high-effort audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional optimal ranges (e.g. fasting insulin 2–5 µIU/mL, hs-CRP below 0.5 mg/L) are tighter than conventional reference ranges.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance separates the large cessation gain for smokers from the small, brief attention gain relevant to non-smoking optimizers.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” is used in the title and header; “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Routes are named formally (“gum, lozenge or low-strength pouch”, “21 mg patch”, “oral and swallowed-saliva formats”); no lay route phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	61 spans present; the repeatable marker_#* and qualitative_item# spans are expanded to marker_1–7 and qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans are untouched; a structural diff against the template shows no other deviations.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce the ER bold labels “Standard non-smoker protocol”, “Conventional replacement-therapy protocol” and “Best time of day” verbatim; marker names match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and Monitoring labels are carried over unchanged.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s “⚠️ Conflicted” markers were stripped from the benefit and risk entries.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is reduced to key facts; gate items, tier entries and monitoring cells carry no rationale, citations or effect sizes beyond what items 8.2, 9.2, 14.2 and 15.2 require.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding title line is outside the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block sits entirely inside an HTML comment; no element echoes the YAML.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: nicotine_2026-0919-0309_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.11 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0919-0601.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: nicotine_2026-0919-0309_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Nicotine for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Nicotine for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0919-0601 → “09/19/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs: the small acute attention effect, the cessation gain, the unconfirmed larger claims and the standing costs.
7.2	[at_a_glance] is no longer than 60 words	🟢	60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 489–491.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“memory loss”, “inflamed bowel” and “blood sugar handling” replace the clinical terms, matching the ER Conclusion’s own plain wording; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only qualitative magnitudes (“briefly and modestly”, “substantially”).

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items trace to ER lines 323 and 337–345.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER “Populations who should avoid Nicotine” entries plus the ER’s stated absolute contraindication for cardiac stress testing.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Ten discrete <li> elements at lines 541–550.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses such as “whose prefrontal circuits are still maturing” and “where nicotine clearance is markedly reduced” are stripped; no dashes carry trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(within 14 days)”, “(above 180/110 mmHg)”, “(within 30 days)”, “(Child-Pugh Class C)”, “(test day; separated by at least 24 hours)” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation; items are plain prose.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to ER lines 317–333.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of the ER’s nine interaction bullets; adenosine/dipyridamole is correctly omitted here because it sits in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight discrete <li> elements at lines 556–563.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Caution/Monitor verdicts and mechanistic sentences are dropped; the ER’s “Other interventions —” prefix is stripped from the varenicline/cytisinicline item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug lists retained for beta-blockers, sulfonylureas, decongestants, stimulant supplements and nicotinic receptor drugs; the ER’s plain-language drug-class glosses are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	Parenthetical drug lists are plain comma-separated; no ranking symbols carried through.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such interactions and the section is populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at lines 369, 371 and 377.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The non-smoker dosing protocol, the cessation replacement-therapy schedule, and timing of dose — the three decisions a user must make first.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides twelve protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; ceilings (4 mg beginners, 8 mg established), the 8–12 week step-down and the mid-afternoon cut-off all come from the ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Oral onset (3–10 minutes), patch onset (1–3 hours) and duration of effect (2–4 hours), from ER lines 420 and 379.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Both onset cells attach to the High-tier acute attention benefit, fastest route first, followed by the duration of that same effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated; “No cumulative benefit that builds over weeks” is taken from ER line 420.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten entries match the ER benefit headings and their tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 521–532).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Benefit headings only; magnitudes, confidence intervals and “⚠️ Conflicted” markers are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven entries match the ER risk headings and their tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 574–585).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk headings only; magnitude figures and the “⚠️ Conflicted” marker on Endothelial Dysfunction are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence trace to the ER Monitoring Protocol & Defining Success section (lines 446–458).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER biomarkers present: Resting Heart Rate, Blood Pressure, Fasting Insulin, HOMA-IR, HbA1c, hs-CRP, Serum or Salivary Cotinine — with targets and rationale matching the ER table.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 1 and 4 weeks then 3–6 months for haemodynamics; 3 months then 6–12 months for the metabolic panel, inflammation marker and cotinine; 6-monthly oral examination — matching ER line 448.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items taken from the ER qualitative-marker list at lines 462–467.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six listed: sleep quality, effect at original dose, inter-dose craving, appetite and weight trend, calm versus jitteriness, and oral comfort.

Issues 19/09/2026 06:33

Pass rate 100.00%. No issues found.

Issues 19/09/2026 06:20

1. 1.3 — Magnitude hedge dropped from lede: at_a_glance (line 433) reads “briefly sharpens attention, reaction speed and fine motor control”, omitting the ER Conclusion’s “a small, brief sharpening” (ER line 489); dropping “small” strengthens the sheet’s headline benefit claim.

Fixes 19/09/2026 06:20

1. 1.3 — Magnitude hedge restored in lede: Rewrote at_a_glance so the ER’s “small, brief” qualification survives — “briefly sharpens” became “briefly and modestly sharpens”. Opening and closing clauses were tightened (“Nicotine without smoke” → “Smoke-free nicotine”; “It is habit-forming, raises” → “Habit-forming, it raises”) to keep the summary at the 60-word ceiling required by 7.2.

Issues 19/09/2026 06:17

1. 7.4 — Clinical-register shorthand in lede: At-A-Glance (line 433) uses “Replacement products”, a truncation of the technical classification “nicotine replacement therapy”; with no antecedent on the sheet its referent is opaque, where the ER Conclusion names the plain-language formats “gum, patches or lozenges” (ER line 489).

Fixes 19/09/2026 06:17

1. 7.4 — Plain-language formats in lede: Replaced “Replacement products” in At-A-Glance with the ER Conclusion’s own plain-language formats, “Gum, patches and lozenges”; “Nicotine apart from smoke” was shortened to “Nicotine without smoke” and “are unconfirmed” to “remain unconfirmed” to hold the lede at exactly 60 words.

Issues 19/09/2026 06:09

1. 1.2 / 1.3 — At-a-glance overstates metabolic harm: Line 433 states “worsens blood sugar handling”, strengthening the ER Conclusion’s hedged “is linked to poorer blood sugar handling with long use” (ER line 491) into a direct causal claim and dropping the long-use restriction, despite the ER noting the underlying data are cross-sectional and open to reverse causation (ER line 261).

Fixes 19/09/2026 06:09

1. 1.2 / 1.3 — At-a-glance metabolic hedging restored: Rewrote the closing clause of [at_a_glance] from “worsens blood sugar handling” to “with long use is linked to poorer blood sugar handling”, matching the ER Conclusion’s associational phrasing and long-use restriction. The sentence on failed larger claims was changed from “have not held up” to “are unconfirmed” and the cessation sentence condensed to “Replacement products substantially raise smokers’ odds of stopping”, keeping the lede at 60 words.